Top Markets
Coin of the day
Clover Biopharmaceuticals, Ltd. Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd.

2197
주식 순위 #15712
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on... Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
주가
$0.25841098
시가총액
$335.38M
변동 (1일)
-2.42%
변동 (1년)
73.70%
국가
CN
거래 Clover Biopharmaceuticals, Ltd. (2197)

카테고리

Clover Biopharmaceuticals, Ltd. (2197)의 주가 이력
최고 종가: $0.26 (2026-09-01 기준)

최저 종가: $1.43 (2021-11-01 기준)
Clover Biopharmaceuticals, Ltd.의 주가 이력 (2021 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -11.59%
2025 858.49%
2024 -56.65%
2023 -82.45%
2022 -72.65%
2021 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$549.03 40.41%
US
$1.02K 43.76%
NL
$147.18 510.96%
US
$121.37 -11.93%
AU
$748.60 4.92%
CH